Throughout human history, technology has been a defining force shaping our civilization, revolutionizing industries, and ...

The Conversation is different because we amplify knowledgeable voices and bring thoughtful ideas to you and your community. As politicians turn up the volume, we provide a respite from the shouting.

This year, as a part of my final paper on gene editing for AP Research, I am gathering data regarding the public's opinion on CRISPR-Cas9, a prevalent gene editing mechanism. If you have a few ...

CRISPR-Cas9 has long been likened to a kind of genetic scissors, thanks to its ability to snip out any desired section of DNA with elegant precision. But it turns out that CRISPR systems have more ...

Jennifer Doudna, the co-developer of CRISPR, says there’s a “coming revolution” in climate-adapted crops and animals. Jennifer Doudna, one of the inventors of the breakthrough gene-editing ...

Explores ethical concerns and risks in self-experimentation, highlighting autonomy, potential harms, and the need for ...

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an impressive resume already, but it's just getting started. It's currently in the ...

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...

Virologist Beata Halassy successfully treated her breast cancer using oncolytic virotherapy, raising ethical questions about self-experimentation in medicine. While her case highlights the potential ...

CRISPR Therapeutics AG (NASDAQ:CRSP) investors still suffer from the stock's tepid momentum. It has also underperformed its healthcare sector (XLV) and biotechnology peers (XBI). As a result, the ...